Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Heparin overview and issues.

Henry Bussey1, John L Francis,

  • 1University of Texas Health Science Center, San Antonio, Texas 78229, USA. bussey@uthscsa.edu

Pharmacotherapy
|September 1, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of Latex Immunoturbidimetric Assay Thresholds and HIT in Cardiothoracic Surgery.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2023
Same author

Evaluation of a rapid and automated heparin-induced thrombocytopenia immunoassay.

International journal of laboratory hematology·2019
Same author

Effects of Oritavancin on Coagulation Tests in the Clinical Laboratory.

Antimicrobial agents and chemotherapy·2016
Same author

Corrigendum to 'Microvesicle-associated tissue factor procoagulant activity for the preoperative diagnosis of ovarian cancer", [Thromb. Res. 141 (2016) 39-48].

Thrombosis research·2016
Same author

Microvesicle-associated tissue factor procoagulant activity for the preoperative diagnosis of ovarian cancer.

Thrombosis research·2016
Same author

CD32a antibodies induce thrombocytopenia and type II hypersensitivity reactions in FCGR2A mice.

Blood·2015
Same journal

Comment on "Pharmacokinetic Analysis of Intravenous Push Cefepime in Critically Ill Patients With Sepsis".

Pharmacotherapy·2026
Same journal

Response to Comment on "Pharmacokinetic Analysis of Intravenous Push Cefepime in Critically Ill Patients With Sepsis".

Pharmacotherapy·2026
Same journal

The Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of Zongertinib in Healthy Male Volunteers.

Pharmacotherapy·2026
Same journal

Menopausal Hormone Therapy: A Narrative Review of Contemporary Evidence.

Pharmacotherapy·2026
Same journal

Getting It Right the Second Time: How Can we Optimize First-Generation Cephalosporin Dosing for Skin and Soft Tissue Infections in the 21st Century?

Pharmacotherapy·2026
Same journal

Buprenorphine Initiation During Extracorporeal Membrane Oxygenation Decreases Sedative and Opioid Exposure: A Retrospective Matched Case-Control Study.

Pharmacotherapy·2026
See all related articles

Unfractionated heparin (UFH) has long been a key anticoagulant, but its limitations and side effects are driving the development of newer agents like low-molecular-weight heparins and fondaparinux.

Area of Science:

  • Pharmacology
  • Hematology
  • Drug Development

Background:

  • Unfractionated heparin (UFH) has been the standard anticoagulant for decades.
  • Its rapid action and short half-life were advantageous, but pharmacokinetic variability and monitoring challenges existed.

Purpose of the Study:

  • To review the historical use and limitations of UFH.
  • To discuss the development and advantages of newer antithrombotic agents.
  • To consider the future role of UFH in light of these advancements.

Main Methods:

  • Literature review of unfractionated heparin and newer anticoagulants.
  • Analysis of pharmacokinetic properties, efficacy, and safety profiles.
  • Discussion of clinical implications and future trends in thrombosis treatment.

Related Experiment Videos

Main Results:

  • UFH, while effective, presents challenges in dosing, monitoring, and adverse effects like heparin-induced thrombocytopenia (HIT).
  • Low-molecular-weight heparins and fondaparinux offer more predictable pharmacokinetics and improved safety profiles.
  • These newer agents provide enhanced therapeutic options for managing thrombosis.

Conclusions:

  • Despite its long-standing utility, the limitations of UFH are becoming more pronounced with the advent of safer and more reliable anticoagulants.
  • The development of low-molecular-weight heparins and synthetic pentasaccharides represents significant progress in antithrombotic therapy.
  • The future may see a reduced reliance on UFH as newer agents become more established.